HCA Stock Analysis — HCA Healthcare
Sector: Healthcare
AI Verdict
HCA is cheap for the sector at 13.9x forward earnings, but you're betting against consensus expectations of falling profits and need a turnaround to justify even this low multiple.
Competitive Moat
HCA operates a vast network of hospitals and surgery centers across the U.S., giving it scale advantages in negotiating with insurers and suppliers. Its regional dominance in several key markets creates high barriers to entry for new competitors.
Summary
RSI at 14.7 signals extreme oversold territory after a flat year and negative earnings outlook.
Where It Stands
HCA trades at 13.9x next year's earnings, well below the healthcare sector median of 22x, with a 1-year return of -0.75% and an RSI of 14.7 indicating deep oversold conditions.
Key Metrics
- RSI: 14.7 — Oversold
- Trailing P/E: 13.0x
- Forward P/E: 13.9x
- Earnings Growth: -0.1%
- Revenue Growth: +0.1%
- Market Cap: $84.0B
- Dividend Yield: 0.01%
- 1-Year Return: -0.75%
- 5-Year Return: 0.7535553806
- 52-Week High: $556.52
- 52-Week Low: $330.00
Analyst Consensus
19 Buy · 10 Hold · 1 Sell (30 analysts) · Target $510.75
Bull Case
The forward P/E of 13.9x prices in a lot of negativity for a dominant hospital operator, and the 5-year return of 75% shows the business has historically compounded value.
Bear Case
With forward EPS expected to shrink by -6.2% and the P/E likely to compress further if results disappoint, another turn lower in the multiple would erase billions from the $84.0B market cap.
Catalyst to Watch
Quarterly earnings updates—any sign that EPS declines are moderating or reversing could trigger a sharp rebound from oversold levels.